论文部分内容阅读
目的探讨地塞米松冲击治疗特发性血小板减少性紫癜的临床疗效。方法 2004-09-2009-12利用地塞米松40 mg×4 d冲击治疗ITP患者40例。结果根据出血症状及血小板上升情况,并根据并发症如合并感染,安全性,与传统的治疗(地塞米松10 mg×7 d)相比,均有明显的优势。血小板上升迅速,出血症状很快得到控制。并发症发生率减少,安全性提高。结论短程地塞米松40 mg×4 d冲击治疗特发性血小板减少性紫癜缩短疗程,起效快,缩短了危险期,不良反应发生率及对人体的危害降低,值得推广,可做为特发性血小板减少性紫癜的有效治疗手段。
Objective To investigate the clinical efficacy of dexamethasone in the treatment of idiopathic thrombocytopenic purpura. Methods From September 2004 to December 2009, 40 patients with ITP were treated with 40 mg × 4 d dexamethasone. Results According to the bleeding symptoms and platelet rise, and according to complications such as infection, safety, compared with the traditional treatment (dexamethasone 10 mg × 7 d), there are obvious advantages. Rapid rise of platelets, bleeding symptoms quickly be controlled. The incidence of complications is reduced and safety is improved. Conclusion Short-course dexamethasone 40 mg × 4 d shock treatment of idiopathic thrombocytopenic purpura shorten the course of treatment, rapid onset, shortening the risk period, the incidence of adverse reactions and reduce the harm to the human body, is worth promoting, can be used as idiopathic Thrombocytopenic purpura effective treatment.